Drug Type Small molecule drug |
Synonyms PLX 200 |
Target |
Mechanism TPP1 stimulants(Tripeptidyl Peptidase 1 stimulants), Apoptosis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization Polaryx Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Fast Track (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuronal Ceroid-Lipofuscinoses | Phase 3 | - | Polaryx Therapeutics, Inc.Startup | 01 Dec 2024 |
Tay-Sachs Disease | Preclinical | US | Polaryx Therapeutics, Inc.Startup | 28 Sep 2021 |
Sandhoff Disease | Preclinical | US | Polaryx Therapeutics, Inc.Startup | 27 Aug 2021 |
Leukodystrophy, Globoid Cell | Preclinical | US | Polaryx Therapeutics, Inc.Startup | 17 Aug 2021 |